NRSN (NeuroSense Therapeutics) Insider Ownership: 5.27 % (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRSN NeuroSense Therapeutics Ltd NRSN
31 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Insider Ownership?

NeuroSense Therapeutics NRSN +2.19% 31 Insider Ownership is 5.27 % as of Jul. 21, 2026. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NeuroSense Therapeutics's insider ownership is 5.27%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NeuroSense Therapeutics's Institutional Ownership is 1.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NeuroSense Therapeutics's Float Percentage Of Total Shares Outstanding is 77.57%.

NeuroSense Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Insider Ownership Chart

NeuroSense Therapeutics Historical Data

The historical data trend for NeuroSense Therapeutics can be seen below:

2026-05-31 2026-06-30
Insider Ownership 4.58 5.27
NRSN
31GF Score
NeuroSense Therapeutics Ltd NRSN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 5.27 % mean?
NeuroSense Therapeutics (NRSN) has a Insider Ownership of 5.27 % as of Jul. 21, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Insider Ownership too high?
NeuroSense Therapeutics' current Insider Ownership is 5.27 %. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Insider Ownership compare to SER and PVCT?
NeuroSense Therapeutics' Insider Ownership of 5.27 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Insider Ownership is 5.27 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Insider Ownership of 5.27 %. The current Insider Ownership is 5.27 %. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Insider Ownership is 5.27 % as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score

Get the complete analysis for NRSN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price